Información del artículo
Resumen
Durante las últimas décadas, las tasas de uso de la terapia hormonal sustitutiva (THS) se han incrementado de forma considerable. Ello implica que en la actualidad reciben este tipo de tratamiento pacientes que no son tan estrictamente seleccionadas como en los inicios de estas terapias. De esta forma, mujeres con enfermedades medicoquirúrgicas son candidatas a la aplicación de THS, por lo que es necesario que el especialista conozca la repercusión negativa o positiva que los estroprogestágenos pueden tener sobre el proceso morboso concreto de cada mujer climatérica. En la presente revisión se pretende hacer un repaso de lo publicado respecto a la THS aplicada a pacientes con enfermedades de alta frecuencia en la población menopáusica así como en otras de una prevalencia menor, pero que es necesario recoger por la tradicionalmente atribuida influencia hormonal sobre éstas, fundamentada o no. Se han excluido las enfermedades que incrementan el riesgo cardiovascular y las afecciones tumorales que, por sus particularidades, han sido objeto frecuente de revisiones con anterioridad
Palabras clave:
Terapia hormonal sustitutiva
Patología del sistema nervioso central
Patología tiroidea
Patología osteoarticular
Patología hepatobiliar
Patología autoinmune
Summary
The use of hormone replacement therapy (HRT) has increased considerably over the last few decades. This implies that patients who currently receive this kind of treatment are not selected as strictly as they were when this therapy first began to be used. Consequently, women with medicalsurgical entities are candidates for the application of HRT, and specialists should be aware of the positive or negative effects of estroprogestogens on the specific morbid process of each menopausal woman. In this review we discuss the literature to date on the use of HRT in morbid processes frequently found in menopausal women, as well as in other processes with a lower prevalence but which cannot be overlooked because of the hormonal influence traditionally attributed to them, whether founded or not. Factors that increase cardiovascular risk and tumoral disease are not discussed because, due to their special characteristics, they have been widely discussed in previous reviews
Keywords:
Hormone replacement therapy
Central nervous system disorders
Thyroid abnormalities
Osteoarticular disorders
Hepatobiliary disease
Autoimmune disorders
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.B. Miller, S.F. Ali, J.P. O'Callaghan, S.C. Laws.
The impact of gender and estrogen on striatal dopaminergic neurotoxicity.
Ann N Y Acad Sci, 844 (1998), pp. 153-165
[2.]
S. Seshadri, G.L. Zornberg, L.E. Derby, M.W. Myers, H. Jick, D.A. Drachman.
Postmenopausal estrogen replacement therapy and the risk of Alzheimer disease.
Arch Neurol, 58 (2001), pp. 435-440
[3.]
G.A. Kuchel, C. Tannenbaum, S.L. Greenspan, N.M. Resnick.
Can variability in the hormonal status of elderly women assist in the decision to administer estrogens?.
J Womens Health Gend Based Med, 10 (2001), pp. 109-116
[4.]
E. Savaskan, G. Olivieri, F. Meier, R. Ravid, F. Muller-Spahn.
Hippocampal estrogen beta-receptor immunoreactivity is increased in Alzheimer's disease.
Brain Res, 908 (2001), pp. 113-119
[5.]
C. Behl.
Estrogens against Alzheimer disease? The female sexual hormone as a protective neurohormone.
MMW Fortschr Med, 143 (2001), pp. 33-35
[6.]
P.S. Green, J.W. Simpkins.
Neuroprotective effects of estrogens: potential mechanisms of action.
Int J Dev Neurosci, 18 (2000), pp. 347-358
[7.]
J.E. Shepherd.
Effects of estrogen on congnition mood, and degenerative brain diseases.
J Am Pharm Assoc (Wash), 41 (2001), pp. 221-228
[8.]
P. Schonknecht, J. Pantel, K. Klinga, M. Jensen, T. Hartmann, B. Salbach, et al.
Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease.
Neurosci Lett, 307 (2001), pp. 122-124
[9.]
D.K. Panidis, I.M. Matalliotakis, D.H. Rousso, A.I. Kourtis, E.E. Koumantakis.
The role of estrogen replacement therapy in Alzheimer's disease.
Eur J Obstet Gynecol Reprod Biol, 95 (2001), pp. 86-91
[10.]
T. Van Amelsvoort, J. Compton.
Murphy in vivo assessment of the effects of estrogen on human brain.
Trends Endocrinol Metab, 12 (2001), pp. 273-276
[12.]
H. Ohtani, M. Nomoto, T. Douchi.
Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats.
Brain Res, 900 (2001), pp. 163-168
[13.]
D.B. Miller, S.F. Ali, J.P. O'Callaghan, S.C. Laws.
The impact of gender and estrogen on striatal dopaminergic neurotoxicity.
Ann N Y Acad Sci, 844 (1998), pp. 153-165
[14.]
C. Leranth, R.H. Roth, J.D. Elswoth, F. Naftolin, T.L. Horvath, D.E Redmond Jr..
Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory.
J Neurosci, 20 (2000), pp. 8604-8609
[15.]
K. Kompoliti.
Estrogen and movement disorders.
Clin Neuropharmacol, 22 (1999), pp. 318-326
[17.]
C.T. Peebles, J.W. McAuley, J.L. Moore, H.J. Malone, A.L. Reeves.
Hormone replacement therapy in a postmenopausal woman with epilepsy.
Ann Pharmacother, 34 (2000), pp. 1028-1031
[18.]
C.L. Harden, M.C. Pulver, L. Ravdin, A.R. Jacobs.
The effect of menopause and perimenopause on the course of epilepsy.
Epilepsia, 40 (1999), pp. 1402-1407
[19.]
P. Crawford, P. Lee.
Gender difference in management of epilepsy-what women are hearing.
Seizure, 8 (1999), pp. 135-139
[20.]
F. Abbasi, A. Krumholz, S.J. Kittner, P. Langenberg.
Effects of menopause on seizures in women with epilepsy.
Epilepsia, 40 (1999), pp. 205-210
[22.]
J.S. Archer.
NAMS/Solvay Resident Essay Award. Relationship between estrogen, serotonin, and depression.
Menopause, 6 (1999), pp. 71-78
[23.]
C.N. Soares, O.P. Almeida, H. Joffe, L.S. Cohen.
Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.
Arch Gen Psychiatry, 58 (2001), pp. 529-534
[24.]
O. Bukulmez, A. Al, H. Gurdal, H. Yarali, B. Ulug, T. Gurgan.
Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial.
Fertil Steril, 75 (2001), pp. 737-743
[25.]
E.F. Binder, K.B. Schechtman, S.J. Birge, D.B. Williams, W.M. Kohrt.
Effects of hormone replacement therapy on cognitive performance in elderly women.
Maturitas, 38 (2001), pp. 137-146
[26.]
S.S. Girdler, C. O'Briant, J. Steege, K. Grewen, K.C. Light.
A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women.
J Womens Health Gend Based Med, 8 (1999), pp. 637-646
[27.]
B. Saletu, N. Brandstatter, M. Metka, M. Stamenkovic, P. Anderer, H.V. Semlitsch, et al.
Double-blind, placebo-controlled, hormonal, syndromal and EEG mapping studies with transdermal oestradiol therapy in menopausal depression.
Psychopharmacology (Berl), 122 (1995), pp. 321-329
[28.]
I. Rudolph, T. Zimmermann, K. Kaminski, K. Jandova, B. Borovsky, H.J. Ahrendt, et al.
Changes in psychic and somatic wellbeing and cognitive capabilities of peri- and postmenopausal women after the use of a hormone replacement drug containing estradiol valerate and levonorgestrel.
Methods Find Exp Clin Pharmacol, 22 (2000), pp. 51-56
[29.]
G. Khastgir, J. Studd.
Hysterectomy, ovarian failure, and depression.
Menopause, 5 (1998), pp. 113-122
[30.]
E. Stadberg, L.A. Mattsson, I. Milsom.
The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population.
Acta Obstet Gynecol Scand, 76 (1997), pp. 442-448
[33.]
T.H. Raudaskoski, E.I. Tomas, I.A. Paakkari, A.J. Kauppila, T.J. Laatikainen.
Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device.
Maturitas, 22 (1995), pp. 47-53
[34.]
C.J. Haines, T.K. Chung, J.R. Masarei, B. Tomlinson, J.T. Lau.
The effect of percutaneous oestrogen replacement therapy on Lp(a) and other lipoproteins.
Maturitas, 22 (1995), pp. 219-225
[35.]
T. Raudaskoski, T. Laatikainen, A. Kauppila.
Sex-hormone binding globulin as an indicator of the hepatic impacts of continuous combined hormone replacement regimens.
Maturitas, 29 (1998), pp. 87-92
[36.]
R.C. Dardes, V.C. Jordan.
Novel agents to modulate oestrogen action.
Br Med Bull, 56 (2000), pp. 773-786
[37.]
M. O'Brien, A. Montes, T.J. Powles.
Hormone replacement therapy as treatment of breast cancer - A phase II study of Org OD 14 (tibilone).
Br J Cancer, 73 (1996), pp. 1086-1088
[38.]
P.M. Sarrel.
Cardiovascular disease in women: implications of hormone replacement therapy.
Int J Fertil Menopausal Stud, 41 (1996), pp. 90-93
[39.]
I.I. Bolaji, G. Mortimer, H. Grimes, D.F. Tallon, E. O'Dwyer, P.F. Fottrell.
Clinical evaluation of near-continuous oral micronized progesterone therapy in estrogenized postmenopausal women.
Gynecol Endocrinol, 10 (1996), pp. 41-47
[40.]
E. Gdansky, U. Beller, M. Neuman, J. Halevy, P.D. Lebensart.
Regression of hepatic tumors during transdermal estradiol replacement therapy.
Acta Obstet Gynecol Scand, 74 (1995), pp. 75-78
[41.]
D. Foth, T. Romer, E. Panzig.
Hepatic changes in different hormone replacement therapies in climacteric].
Zentralbl Gynakol, 117 (1995), pp. 349-352
[42.]
K.K. Ho, A.J. O'Sullivan, A.J. Weissberger, J.J. Kelly.
Sex steroid regulation of growth hormone secretion and action.
Horm Res, 45 (1996), pp. 67-73
[43.]
N. Gitlin, P. Korner, H.M. Yang.
Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials.
Menopause, 6 (1999), pp. 216-224
[44.]
M.M. Gelfand, B. Wiita.
Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996.
Clin Ther, 19 (1997), pp. 383-404
[45.]
C. La Vecchia, L.A. Brinton, A. McTiernan.
Menopause, hormone replacement therapy and cancer.
Maturitas, 39 (2001), pp. 97-115
[46.]
K. Chida, M. Shirai, M. Sato, J. Sato, H. Nakamura.
Successful treatment of hepatic sarcoidosis with hormone replacement in a postmenopausal woman.
Respirology, 4 (1999), pp. 259-261
[47.]
T.M. Ng, I.E. Bajjoka.
Treatment options for osteoporosis in chronic liver disease patients requiring liver transplantation.
Ann Pharmacother, 33 (1999), pp. 233-235
[49.]
J.M. Foidart, J. Desreux, A. Pintiaux, L. Moreau.
Transdermal replacement hormone therapy: a trend or an advantage?.
Rev Med Liege, 53 (1998), pp. 208-211
[50.]
M.L. Uhler, J.W. Marks, H.L. Judd.
Estrogen replacement therapy and gallbladder disease in postmenopausal women.
Menopause, 7 (2000), pp. 162-167
[51.]
A. Tavani, E. Negri, C. La Vecchia.
Menstrual and reproductive factors and biliary tract cancers.
Eur J Cancer Prev, 5 (1996), pp. 241-247
[52.]
I. Persson, J. Yuen, L. Bergkvist, C. Schairer.
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort.
Int J Cancer, 67 (1996), pp. 327-332
[53.]
R. Olsson, L.A. Mattsson, K. Obrant, D. Mellstrom.
Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis.
Liver, 19 (1999), pp. 188-192
[55.]
Z.J. Bulaj, M.R. Franklin, J.D. Phillips, K.L. Miller, H.A. Bergonia, R.S. Ajioka, et al.
Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda.
J Lab Clin Med, 136 (2000), pp. 482-488
[56.]
M.C. Nevitt, D.T. Felson, E.N. Williams, D. Grady.
The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 44 (2001), pp. 811-818
[57.]
D.T. Felson, M.C. Nevitt.
The effects of estrogen on osteoarthritis.
Curr Opin Rheumatol, 10 (1998), pp. 269-272
[58.]
T.D. Spector, D. Nandra, D.J. Hart, D.V. Doyle.
Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford Study.
Ann Rheum Dis, 56 (1997), pp. 432-434
[59.]
H. Sandmark, C. Hogstedt, S. Lewold, E. Vingard.
Osteoarthrosis of the knee in men and women in association with overweight, smoking, and hormone therapy.
Ann Rheum Dis, 58 (1999), pp. 151-155
[60.]
E.M. Dennison, N.K. Arden, S. Kellingray, P. Croft, D. Coggon, C. Cooper.
Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study.
Br J Rheumatol, 37 (1998), pp. 1198-1202
[61.]
J.P. Hatch, J.D. Rugh, S. Sakai, M.J. Saunders.
Is use of exogenous estrogen associated with temporomandibular signs and symptoms?.
J Am Dent Assoc, 132 (2001), pp. 319-326
[63.]
K.A. Head.
Ipriflavone: an important bone-building isoflavone.
Altern Med Rev, 4 (1999), pp. 10-22
[65.]
C.G. Ogard, C. Ogard, T.P. Almdal.
Thyroid-associated orbitopathy developed during hormone replacement therapy.
Acta Ophthalmol Scand, 79 (2001), pp. 426-427
[66.]
G. Barbesino, Y. Tomer, E.S. Concepcion, T.F. Davies, D.A. Greenberg.
Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome. International Consortium for the Genetics of Autoimmune Thyroid Disease.
J Clin Endocrinol Metab, 83 (1998), pp. 3290-3295
[67.]
Y. Hori, K. Kashima, T. Daa, S. Yokoyama, I. Nakayama, S. Noguchi.
Relationship between cell proliferation activity and morphological characteristics of papillary microcarcinoma in the thyroid of Graves' disease.
Pathol Int, 45 (1995), pp. 846-853
[68.]
J. Foldes, P. Lakatos, J. Zsadanyi, C. Horvath.
Decreased serum IGF-I and dehydroepiandrosterone sulphate may be risk factors for the development of reduced bone mass in postmenopausal women with endogenous subclinical hyperthyroidism.
Eur J Endocrinol, 136 (1997), pp. 277-281
[69.]
B.L. Langdahl, A.G. Loft, N. Moller, J. Weeke, E.F. Eriksen, L. Mosekilde, et al.
Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?.
J Bone Miner Res, 12 (1997), pp. 78-88
[70.]
B.M. Arafah.
Increased need for thyroxine in women with hypothyroidism during estrogen therapy.
N Engl J Med, 344 (2001), pp. 1743-1749
[72.]
M. Cutolo.
Sex hormone adjuvant therapy in rheumatoid arthritis.
Rheum Dis Clin North Am, 26 (2000), pp. 881-895
[73.]
Y. Suzuki, R. Uehara, M. Ide, Y. Ichikawa.
Osteoporosis in rheumatoid arthritis].
Nippon Rinsho, 56 (1998), pp. 1598-1603
[74.]
M.H. Liang, E.W. Karlson.
Female hormone therapy and the risk of developing or exacerbating systemic lupus erythematosus or rheumatoid arthritis.
Proc Assoc Am Physicians, 108 (1996), pp. 25-28
[75.]
E.J. Mayeaux Jr., C. Johnson.
Current concepts in postmenopausal hormone replacement therapy.
J Fam Pract, 43 (1996), pp. 69-75
[76.]
W. Siegmeth, A. Fellmann-Bauer, G. Nahler.
Hormonal status of the woman and its effect on symptoms and progression of chronic polyarthritis].
Acta Med Austriaca, 23 (1996), pp. 124-128
[77.]
C.C. Mok, C.S. Lau, R.W. Wong.
Use of exogenous estrogens in systemic lupus erythematosus.
Semin Arthritis Rheum, 30 (2001), pp. 426-435
[78.]
M. Petri.
Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy.
Lupus, 10 (2001), pp. 222-226
[79.]
S. Kreidstein, M.B. Urowitz, D.D. Gladman, J. Gough.
Hormone replacement therapy in systemic lupus erythematosus.
J Rheumatol, 24 (1997), pp. 2149-2152
[80.]
J. Sanchez-Guerrero, M.H. Liang, E.W. Karlson, D.J. Hunter, G.A. Colditz.
Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus.
Ann Intern Med, 122 (1995), pp. 430-433
[81.]
D.T. Boumpas, B.J. Fessler, H.A. Austin, J.E. Balow, J.H. Klippel, M.D. Lockshin.
Systemic lupus erythematosus: emerging concepts. Part 2. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis.
Ann Intern Med, 123 (1995), pp. 42-53
[82.]
C.C. Mok, C.S. Lau, C.T. Ho, K.W. Lee, M.Y. Mok, R.W. Wong.
Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus.
Scand J Rheumatol, 27 (1998), pp. 342-346
[83.]
J.P. Buyon.
Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus.
J Am Med Womens Assoc, 53 (1998), pp. 13-17
[84.]
D. Le Thi Huong, B. Wechsler, J.C. Piette.
Effect of pregnancy, menopause and hormone substitution therapy on disseminated systemic lupus erythematosus.
Presse Med, 29 (2000), pp. 55-60
[86.]
R.M. Nagler, S. Pollack.
Sjogren's syndrome induced by estrogen therapy.
Semin Arthritis Rheum, 30 (2000), pp. 209-214
Copyright © 2003. Sociedad Española de Ginecología y Obstetricia